Skip to content
drillr.ai
Sign up

TRDA

Entrada Therapeutics, Inc.

NASDAQ · Healthcare · Biotechnology · US

$6.75
−2.17%
Ask drillr

  • Sep 10, 2026, 11:00 UTC

    Entrada Therapeutics announced the recipients of its 2026 DREAMS Grant Program, awarding two $50,000 grants to support projects addressing healthcare disparities in the Duchenne muscular dystrophy community.

    Source:

  • Aug 5, 2026, 00:00 UTC

    Entrada Therapeutics reported Q2 2026 financial results with revenue of $0.9 million, a net loss of $42.8 million, and diluted EPS of -$1.01, compared to revenue of $2.0 million and a net loss of $43.1 million in Q2 2025.

    Source: